Fibrocell Science, Inc. Completes $9.1 Million Capital Raise

Fibrocell Science, Inc. Completes $9.1 Million Capital Raise

Marina Maher Communications, Inc.Christina Fuschetto(212) 485-6917orICRSherry Bertner(646) 277-1247

Fibrocell Science, Inc. (OTCBB: FCSC) announced today that it has completed a private placement originally commenced in May 2012 pursuant to which it raised an aggregate of $9.1 million through the issuance of preferred stock and warrants.

John Carris Investments LLC and John Thomas Financial, Inc. acted as co-placement agents for the transaction.

For complete details on the transaction, including the details of the preferred stock and warrants, please see the Current Report on Form 8-K filed with the Securities and Exchange Commission on July 16, 2012.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy securities. None of the shares to be issued to the investors nor the shares underlying the preferred stock and warrants issued to the investors will be or have been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

LAVIV was approved by the FDA on June 21, 2011 for the improvement of the appearance of moderate-to-severe nasolabial fold wrinkles in adults and is the first and only personalized cell therapy approved by the FDA for aesthetic use. LAVIVis now available in major metropolitan areas throughout the U.S., exclusively through board-certified dermatologists and plastic surgeons who have been trained by Fibrocell Science on the treatment process. A list of trained and certified physicians is available at and will be continually updated as new physicians are trained and begin offering LAVIV in their practice.

Fibrocell Science is conducting research to identify other potential uses of LAVIV and their proprietary fibroblast technology. There is no timeline regarding when Fibrocell Science will seek FDA regulatory approval for additional uses.

LAVIV is made especially for you from your own skin cells. Using someone else’s cells can cause a serious reaction. Prior to injection, confirm with your physician that your information on the LAVIV vial is correct. The most common side effects of LAVIV are at the injection-site, including redness, bruising, swelling, pain, bleeding, lumps, irritation, and itchiness. In clinical trials with LAVIV, most injection-site adverse reactions resolved within one week and most required no treatment. Your health care provider will help you to decide whether you are a candidate for LAVIV and may help you avoid some of the adverse reactions from LAVIV.

Before getting LAVIV, tell your healthcare provider if you have any medical problems including allergic reactions to any drugs or food, bleeding disorders or take blood-thinning medicines like aspirin, ibuprofen, or Coumadin® (warfarin sodium), keloids or excessive scarring, skin cancer or any malignancy, genetic disorders affecting your skin, immune problems or take medicines that affect your immune system, or any other illness or medical problem. The full Prescribing Information for LAVIV includes additional warnings about adverse reactions that occurred in less than 1% of patients following LAVIV treatment in clinical trials. Talk to your healthcare provider about these warnings. Please tell your healthcare provider if you are allergic to the antibiotics amphotericin or gentamicin, bovine materials (products made from cattle), or dimethyl sulfoxide(DMSO).

Do not use LAVIV if you have a skin infection on your face because LAVIV treatment can make the infection worse.

Please see the accompanying full prescribing information for LAVIV contraindications, warnings, precautions and adverse events or visit .

Fibrocell Science, Inc. (OTCBB:FCSC.OB) is an autologous cellular therapeutic company focused on the development of innovative products for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well as its innovative cellular processing technology and manufacturing excellence. For additional information, please visit .

Suggested Articles

NGM's aldafermin beat placebo at reversing liver scarring and inflammation, as well as reducing liver fat buildup in a 78-patient study.

The agreement sees Grifols waive a $32 million debt and pay $3 million in cash to take full ownership of three assets.

Astellas’ Xospata and Novartis’ Rydapt may help treat lung cancer that has grown resistant to EGFR inhibitors, researchers discovered.